Patents Assigned to Merck
  • Publication number: 20220024964
    Abstract: A class of polycyclic compounds of general formula (I), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2a, R3, R3a, R4, R5, R5a, R6, R6a, R7, R7a, R8, R8a, and R9 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds (I).
    Type: Application
    Filed: December 2, 2019
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Wonsuk Chang, Jared N. Cumming, Hong Liu, Benjamin Wesley Trotter
  • Publication number: 20220023285
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Application
    Filed: October 15, 2021
    Publication date: January 27, 2022
    Applicants: MERCK SHARP & DOHME CORP., EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Andrew Evan DENKER, Yu KATO, Kimiyo TABATA, Yusaku HORI
  • Publication number: 20220026770
    Abstract: A switchable window element (10) having a layer structure is proposed. The layer structure comprises a switchable layer (20), two polarizers and two optical retarders, wherein a first polarizer and a first optical retarder are arranged in an optical path (40) prior to the switchable layer (20) and a second polarizer and a second optical retarder are arranged in the optical path (40) after the switchable layer (20). Further, the switchable layer (20) is a vertically aligned liquid crystal layer comprising a liquid crystalline medium, wherein the product of the thickness d of the switchable layer (20) and the optical anisotropy ?n of the liquid crystalline medium is in the range of from 0.05 ?m to 3.0 ?m and the liquid crystalline medium has a clearing point of at least 70° C. Further aspects of the invention relate to the use of the switchable window element as window for a building or a vehicle.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 27, 2022
    Applicant: Merck Patent GmbH
    Inventors: Michael JUNGE, Andreas BEYER
  • Publication number: 20220025042
    Abstract: Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
    Type: Application
    Filed: July 16, 2021
    Publication date: January 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
  • Patent number: 11230547
    Abstract: The instant invention provides compounds of formulas Ia and Ib which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Meredeth A. McGowan, Jason D. Katz, Matthew Christopher, Hua Zhou, David James Witter, Chaomin Li, John Lampe, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu
  • Patent number: 11230543
    Abstract: The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Haifeng Tang, Weiguo Liu, Fa-Xiang Ding, Wanying Sun, Yi Zang, Weidong Pan, Anthony Ogawa, Linda Brockunier, Xianhai Huang, Hongwu Wang, Rudrajit Mal, Tesfaye Biftu, Min Park, Yan Guo, Jinlong Jiang, Helen Y. Chen, Christopher W. Plummer
  • Patent number: 11232572
    Abstract: A system and method are disclosed for segmenting a set of two-dimensional CT slices corresponding to a lesion. In an embodiment, for each of at least a subset of the set of CT slices, the system inputs the CT slice into a plurality of branches of a trained segmentation block. Each branch of the segmentation block includes a convolutional neural network (CNN) with filters at a different scale, and produces one or more levels of output. The system generates, for each CT slice in the subset, feature maps for each level of output. The system generates a segmentation of each CT slice in the subset based on the feature maps of each level of output. The system aggregates the segmentations of each slice in the subset to generate a three-dimensional segmentation of the lesion. The system transmits data representing the three-dimensional segmentation to a user interface for display.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Antong Chen, Gregory Goldmacher, Bo Zhou
  • Patent number: 11230556
    Abstract: The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 25, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xiaolei Gao, Sandra L. Knowles, Chunsing Li, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Debra L. Ondeyka
  • Patent number: 11230591
    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 25, 2022
    Assignees: Merck Sharp & Dohme Corp., The Board of Regents, The University of Texas System
    Inventors: Tong-Ming Fu, Aimin Tang, Dai Wang, Zhiqiang An, Ningyan Zhang, Sha Ha
  • Patent number: 11229577
    Abstract: The present invention relates to a process for the preparation of a solid pharmaceutical administration form using a 3D printing process as well. The process is a printing process that allows the production of solid pharmaceutical administration forms in a flexible manner and in conformity with the high quality standards required for the production of pharmaceuticals.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: January 25, 2022
    Assignee: Merck Patent GmbH
    Inventors: Stefan Schiller, Andrea Hanefeld, Gerhard Jonschker
  • Patent number: 11230764
    Abstract: Methods of forming metal-containing films by atomic layer deposition are provided. The methods include delivering a metal-containing complex, a purge gas, and a co-reactant to a first substrate under sufficient conditions such that the metal-containing film selectively grows on at least a portion of the first substrate.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: January 25, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Jean-Sébastien Lehn, Charles Dezelah, Jacob Woodruff
  • Publication number: 20220017525
    Abstract: The present invention is directed to cyclobutyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhuyan Guo, Zhong Lai, Dongfang Meng
  • Publication number: 20220016121
    Abstract: The present invention is directed to a crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid to sodium is from 1:0.5 to 1:1.5 (in mol/mol) and/or hydrates and/or solvates thereof, as well as, a processes of obtaining the same.
    Type: Application
    Filed: July 28, 2021
    Publication date: January 20, 2022
    Applicant: Merck Patent GmbH
    Inventors: Rudolf MOSER, Viola GROEHN, Fritz BLATTER, Martin SZELAGIEWICZ, Ruth BOEHNI STAMM, Markus RUETTIMANN, Giuseppe LAPADULA
  • Publication number: 20220017526
    Abstract: The present invention is directed to amino and alkyl pyrazolopyrimidine compounds which may be useful as therapeutic agents for the treatment of disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating cardiovascular and cerebrovascular diseases, such as hypertension, chronic kidney disease and heart failure, and neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ashok Arasappan, Jason M. Cox, John S. Debenham, Zhe Feng, Zhuyan Guo, Dongfang Meng
  • Publication number: 20220016816
    Abstract: The present invention relates to a two-step process for the production of virtual three-dimensional patterns in polymeric mouldings with the aid of injection-moulding processes, in particular a process in which a conventional injection-moulding process are combined with a reactive injection-moulding process in a suitable manner in order to obtain polymeric mouldings having a virtual three-dimensional pattern which is visible on one surface and is formed by flake-form effect pigments, and to the polymeric mouldings produced by means of this process and to the use thereof, in particular for decorative purposes.
    Type: Application
    Filed: December 2, 2019
    Publication date: January 20, 2022
    Applicant: MERCK PATENT GMBH
    Inventors: Marc HUNGER, Laurent DELOUX
  • Publication number: 20220017851
    Abstract: Disclosed are a process and an automated facility for manufacturing a purified protein of interest. The protein of interest can be a recombinant or naturally occurring protein and/or a therapeutic or other medically useful protein. For example, the disclosed process and automated facility are useful for manufacturing a purified protein drug substance.
    Type: Application
    Filed: August 8, 2021
    Publication date: January 20, 2022
    Applicants: Just-Evotec Biologics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Michael Wayne Vandiver, Eva Fan Gefroh, Rebecca Eileen McCoy, Robert James Piper, JR., Mark A. Brower, Nuno J. Dos Santos Pinto, William N. Napoli, Rachel Y. Straughn, Lisa A. Connell-Crowley, Megan J. McClure
  • Publication number: 20220016031
    Abstract: A process for preparing and isolating pharmaceutical active ingredient particles having a particle size of between about 0.1 and 30 microns, wherein a slurry comprising the active ingredient and one or more pharmaceutically acceptable excipients is fed into a thin film evaporator under suitable conditions for less than 10 minutes sufficient to generate solid matrix particles comprising active ingredient and one or more excipients, wherein the particles have less than 5% residual solvent.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 20, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Luke R. Schenck, David J. Lamberto, Joseph L. Kukura, II, Francisco J. Guzman, Aaron Cote, Athanas Koynov
  • Patent number: 11225471
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I).
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: January 18, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Steven L. Colletti, Duane DeMong, Kevin D. Dykstra, Zhiyong Hu, Michael Miller
  • Patent number: 11225606
    Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal media comprising them, and to the use of the polymerizable compounds and liquid crystalline media for optical, electro-optical and electronic purposes, in particular in liquid crystalline displays, especially in liquid crystalline displays of the polymer sustained alignment type.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: January 18, 2022
    Assignee: MERCK PATENT GMBH
    Inventors: Qiong Tong, Nico Schwebel, Constanze Brocke, Kaja Deing, Julian Vogt, Elisabeth Meyer
  • Publication number: 20220010016
    Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.
    Type: Application
    Filed: October 17, 2019
    Publication date: January 13, 2022
    Applicants: BioLineRx Ltd., Merck Sharp & Dohme Corp.
    Inventors: Abi VAINSTEIN-HARAS, Ella SORANI, Irit GLIKO-KABIR, Osnat BOHANA-KASHTAN, Amnon PELED